Advertisement
Advertisement
U.S. Markets open in 9 hrs 10 mins
Advertisement
Advertisement
Advertisement
Advertisement

Lipella Pharmaceuticals Inc. (LIPO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.7400+0.2600 (+10.48%)
At close: 03:59PM EST
2.6600 -0.08 (-2.92%)
After hours: 05:45PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.4800
Open2.4400
Bid2.6700 x 900
Ask2.7800 x 800
Day's Range2.4101 - 2.8100
52 Week Range2.3100 - 7.7200
Volume219,596
Avg. Volume949,033
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10

    Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications, today announced top line results of the Company's recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for Hemorrhagic Cystitis, a rare but highly morbid disease for whi

  • PR Newswire

    Lipella Pharmaceuticals to Present at January 2023 Biotech Showcase in San Francisco

    Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications, today announced that Dr. Jonathan Kaufman, Co-Founder, Chairman, and CEO will be presenting at Biotech Showcase™ 2023. The Biotech Showcase Conference is taking place in San Francisco in parallel to the J.P. Morgan (JPM) 41s

  • PR Newswire

    Lipella Announces Closing of Initial Public Offering for Gross Proceeds of $7 Million

    Lipella Pharmaceuticals Inc. ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications, today announced the closing of its initial public offering of 1,217,391 shares of its common stock at a price to the public of $5.75 per share. The gross proceeds from the offering to Lipella, before deducting the underwriting discounts an

Advertisement
Advertisement